Literature DB >> 3488149

T cell function in systemic lupus erythematosus: normal production of and responsiveness to interleukin 2.

A M Draeger, A J Swaak, H G van den Brink, L A Aarden.   

Abstract

To investigate the role of interleukin 2 (IL-2) in systemic lupus erythematosus (SLE) mononuclear cells (MNC) of 68 SLE patients were tested for their ability to produce and also to respond to IL-2. Cells were collected monthly over an one year period. IL-2 production by MNC was measured under various conditions after optimal and suboptimal stimulation. Although we found a large variation in IL-2 production by individual MNC preparations no statistical significant differences were found between normal and SLE cells. To study IL-2 responsiveness, proliferation of MNC was studied under conditions where endogenous IL-2 production is limiting. Addition of IL-2 resulted in a four- to eight-fold enhancement of proliferative responses. However also in this respect no differences were found between SLE patients and healthy controls. Thus, in this group of SLE patients no abnormalities in IL-2 production or response could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488149      PMCID: PMC1542159     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  38 in total

1.  Lack of suppressor cell activity in systemic lupus erythematosus.

Authors:  B Newman; S Blank; R Lomnitzer; P Disler; A R Rabson
Journal:  Clin Immunol Immunopathol       Date:  1979-06

2.  Signal requirements for T lymphocyte activation. I. Replacement of macrophage function with phorbol myristic acetate.

Authors:  D L Rosenstreich; S B Mizel
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

3.  Altered function of suppressor T lymphocytes in patients with active systemic lupus erythematosus--in vitro immune response to autoantigen.

Authors:  C Morimoto; T Abe; M Homma
Journal:  Clin Immunol Immunopathol       Date:  1979-06

4.  Immunoregulatory aberrations in systemic lupus erythematosus.

Authors:  A S Fauci; A D Steinberg; B F Haynes; G Whalen
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

5.  Significance of persisting serologic abnormalities in SLE.

Authors:  R W Lightfoot; G R Hughes
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

6.  Characteristics of anti-T-cell antibodies in systemic lupus erythematosus: evidence for selective reactivity with normal suppressor cells defined by monoclonal antibodies.

Authors:  C Morimoto; E L Reinherz; T Abe; M Homma; S F Schlossman
Journal:  Clin Immunol Immunopathol       Date:  1980-08

7.  Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus.

Authors:  T Sakane; A D Steinberg; I Green
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

8.  Suppressor cell defect in SLE: relationship to native DNA binding.

Authors:  R S Krakauer; J D Clough; T Alexander; J Sundeen; D N Sauder
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

9.  Interleukin 2 induces T cell-dependent IgM production in human B cells.

Authors:  R W Sauerwein; W G Van der Meer; A Dräger; L A Aarden
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

10.  Two distinct factors are required for induction of T-cell growth.

Authors:  E L Larsson; N N Iscove; A Coutinho
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

View more
  9 in total

1.  Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE).

Authors:  J F Viallard; J L Pellegrin; V Ranchin; T Schaeverbeke; J Dehais; M Longy-Boursier; J M Ragnaud; B Leng; J F Moreau
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

Review 2.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Cellular aspects of myasthenia gravis.

Authors:  S Berrih-Aknin; S Cohen-Kaminsky; D Neumann; D Safar; B Eymard; C Gaud; P Levasseur; S Fuchs; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Defective in vitro IL-2 production in lupus is an early but secondary event paralleling disease activity: evidence from the murine parent-into-F1 model supports staging of IL-2 defects in human lupus.

Authors:  Charles S Via; Gene M Shearer
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

6.  Functional T cell subpopulations responsible for hyposecretion of IL-2 in patients with systemic lupus erythematosus.

Authors:  T Hayama; N Kubo; E Ikeda; H Hashimoto; S Sawada; T Horie
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

7.  T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity.

Authors:  B L Bermas; M Petri; D Goldman; B Mittleman; M W Miller; N I Stocks; C S Via; G M Shearer
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

8.  Interleukin-1-production by monocytes from patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

9.  Spontaneous production of B cell growth factors by SLE lymphocytes.

Authors:  B K Pelton; A M Denman
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.